Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 18, 2026

JPMorgan has stark message on Qualcomm stock

View original at finance.yahoo.com
JPMorgan has stark message on Qualcomm stock JPMorgan is becoming more cautious on QUALCOMM Incorporated (QCOM) ahead of its upcoming earnings report, citing rising pressure in its core handset business…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Fiscal Q2 2026 non-GAAP EPS guidance of $2.45 to $2.65

    60% confidence

  • Fiscal Q2 2026 revenue guidance of $10.2 billion to $11.0 billion

    60% confidence

  • Meaningful near-term downside risk with no clear event likely to improve the outlook for Qualcomm

    60% confidence

  • Rising pressure in Qualcomm's core handset business with newer growth areas not yet large enough to offset weakness

    60% confidence

  • QCT EBT margin guidance of 26-28% for fiscal Q2 2026, down from 31% previously

    60% confidence

  • QCT revenue expected to decline 22% in calendar 2026

    60% confidence

  • Qualcomm's stock may not be cheap relative to normalized earnings power if handset weakness persists

    60% confidence

Data points we hold from this source

Qualcomm Incorporated · price target140 USD
Qualcomm Incorporated · previous price target185 USD
Qualcomm Incorporated · eps guidance low2.45 USD
Qualcomm Incorporated · eps guidance high2.65 USD
Qualcomm Incorporated · eps3.50 USD
Qualcomm Incorporated · revenue guidance high11.0 USD
Qualcomm Incorporated · revenue guidance low10.2 USD
Qualcomm Incorporated · consensus revenue12.21 USD
Qualcomm Incorporated · consensus eps3.39 USD

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com
JPMorgan has stark message on Qualcomm stock — Source | Via News | Finance Via News